Clinical Trial Update: A Study to Evaluate the Pharmacokinetics and Safety of BEY2153 in Healthy Participants [Phase 1]

View source ↗

Summary

Phase 1 study assessing pharmacokinetics and safety of BEY2153 in healthy participants has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• BEY2153 (BEY2153)

Snippet

Sponsor: BeyondBio Inc. | Conditions: Alzheimer's Disease | Phase 1 | Status: COMPLETED